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We characterized 670 Clostridium difﬁ  cile isolates col-
lected from patients in 84 hospitals in Germany in 2008. 
PCR ribotyping showed high prevalence of ribotype 001 
and restricted dissemination of ribotype 027 strains. Fluo-
roquinolone resistance and associated gyrase mutations 
were frequent in various ribotypes, but no resistance to met-
ronidazole or vancomycin was noted. 
D
uring the past decade, incidence rates of Clostridium 
difﬁ  cile infections (CDI) have increased noticeably 
worldwide (1). In the United States and Canada, this in-
crease has been associated with the emergence of a possi-
bly more virulent strain designated North American pulso-
type 1 (NAP1), or PCR ribotype 027. Strains with identical 
typing patterns have also been reported from several coun-
tries in Europe (1). In Germany, the ﬁ  rst clusters of infec-
tions with C. difﬁ  cile ribotype 027 were identiﬁ  ed in the 
southwest region in 2007 (2,3). Although incidence rates 
increased in Germany after 2000 (4), an association with 
particular strains remains unclear, and no nationwide sur-
veillance data on C. difﬁ  cile genotype prevalence exist.
We report the distribution and associated antimicrobial 
drug susceptibility of prevalent C. difﬁ  cile strains in 
Germany. Isolates were characterized by PCR ribotyping (5) 
by using the ribotype nomenclature of the Cardiff Anaerobe 
Reference Laboratory (Cardiff, Wales, UK). Antimicrobial 
drug susceptibility to therapeutic drugs (metronidazole 
and vancomycin) and to ﬂ  uoroquinolones (moxiﬂ  oxacin 
and levoﬂ   oxacin) was determined by using the Etest 
method (breakpoints according to European Committee on 
Antimicrobial Susceptibility Testing guidelines).
The Study
A surveillance study, performed from January through 
December 2008, reported 5,640 CDI cases in a sample of 
1.6 million patients in hospitals in Germany (www.nrz-hy-
giene.de). Six percent of cases were deﬁ  ned as severe CDI 
based on the following criteria: readmission to a healthcare 
facility due to recurrent CDI, admission to an intensive care 
unit, surgical intervention (colectomy), or death within 30 
days after diagnosis. By projecting these case rates to all 
of Germany (17 million patients 2008; www.destatis.de), 
we estimated 58,000 CDI cases (including 3,500 severe 
cases) in 2008. The 670 isolates investigated in this study, 
which caused severe infections in 84 hospitals throughout 
Germany in 2008, represent ≈20% of those severe CDI 
cases. Among these isolates, 57 ribotypes were identiﬁ  ed, 
and 312 isolates were characterized as PCR ribotype 001 
(47%), followed by 53 (8%) isolates each of ribotypes 078 
and 027. Figure 1 shows the distribution of the 5 most com-
mon ribotypes in proportion to the number of submitting 
hospitals.
Ribotype 001 was by far the most prevalent ribotype 
found, causing severe CDI in 70% of all collaborating hos-
pitals (Figure 1). A high prevalence of ribotype 001 was 
also reported in a recent study investigating 2 hospitals in 
southern Germany (6). As depicted in Figure 2, strains of 
ribotype 001 are endemic to hospitals all over Germany. In 
contrast, the dissemination of ribotype 027 strains, which 
could be identiﬁ  ed in 16 hospitals (19%), is restricted most-
ly to the southwest region of Germany; only 2 sporadic cas-
es were observed in the eastern region (Figure 2). The sec-
ond most prevalent ribotype was 078 (23%). An increasing 
incidence of infections with 078 was observed in several 
European countries, and a zoonotic source is widely de-
bated (7). Isolates of ribotype 014 and 046 were identiﬁ  ed 
in 15% and 10% of all participating hospitals respectively 
and are widespread in neighboring countries (7).
Antimicrobial drug susceptibility testing showed that 
all tested isolates were susceptible to metronidazole and 
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Figure 1. Prevalent PCR ribotypes of Clostridium difﬁ  cile in hospitals 
in Germany, 2008. Eighty-four hospitals sent isolates from patients 
with severe C. difﬁ  cile infections to the Robert Koch Institute. 
Ribotype 001, responsible for severe infections in 59 hospitals 
(70%), was the most prevalent ribotype, followed by ribotype 078 
(19 hospitals, 23%), ribotype 027 (16 hospitals, 19%), ribotype 014 
(13 hospitals, 15%), and ribotype 046 (8 hospitals, 10%).vancomycin. The mean MICs for metronidazole and van-
comycin were calculated for each of the 7 most common 
ribotypes (Table 1). In contrast to a previous study from 
the United Kingdom, there were no signiﬁ  cant differences 
in the mean MICs of metronidazole of common ribotypes 
001, 078, and 027 compared with ribotypes 014, 046, 012, 
and 015 (p = 0.12, Student unpaired t test) (8).
Exposure to ﬂ   uoroquinolones was described as an 
independent risk factor for CDI (9). Type 001 and 027 
isolates from Germany showed widespread resistance to 
moxiﬂ  oxacin and levoﬂ  oxacin (Table 2). In several studies, 
acquisition of ﬂ  uoroquinolone resistance in C. difﬁ  cile has 
been associated with mutations in the active site of DNA 
gyrase (10–12). Sequence analysis of subunits gyrA and 
gyrB showed that most drug-resistant isolates (including 
ribotypes 001, 078, 027, 014, and 046) shared the same sin-
gle transition mutation (ACT to ATT) in gyrA, resulting in 
the amino acid substitution Thr-82→Ile (Table 2). One iso-
late of type 001 possessed a Thr-82→Ile and Asp-71→Glu 
(GAC to GAA) mutation and 1 isolate of type 078, resistant 
to levoﬂ  oxacin (MIC >32 mg/L) but susceptible to moxi-
ﬂ  oxacin (MIC = 2 mg/L), showed a Thr-82→Ala (ACT to 
GCT) change. In addition, high-level resistance (MIC >32 
mg/L) to both ﬂ  uoroquinolones was found in 2 isolates of 
type 014 and 078 associated with mutations in gyrB, al-
though no mutations in gyrA were observed.
The gyrA mutations Thr-82→Ala and Asp-71→Glu 
have not been reported. However, several amino acid sub-
stitutions at both positions were noted before, indicating 
that Thr-82 and Asp-71 in gyrA play a major role in confer-
ring ﬂ  uoroquinolone resistance in C. difﬁ  cile (10–12). The 
Thr-82→Ile substitution especially has been associated with 
ﬂ  uoroquinolone resistance in C. difﬁ  cile by several groups 
(10–12). For instance, Spigaglia et al. described this sub-
stitution in 77 ﬂ  uoroquinolone-resistant isolates afﬁ  liated 
with 19 ribotypes collected in 12 countries in Europe (10). 
Thr-82 in C. difﬁ  cile corresponds to Ser-83 in the quinoline 
resistance–determining region of Escherichia coli (11), and 
mutations at homologous positions have been associated 
with ﬂ  uoroquinolones resistance in several bacteria (13).
Fluoroquinolone resistance has been suggested to pro-
vide a selective advantage for the spread of epidemic C. 
difﬁ  cile strains (8,9,14). However, resistance arose conver-
gently in C. difﬁ  cile ribotypes as a consequence of selec-
tive pressure resulting from widespread ﬂ  uoroquinolone 
use. Because identical mutations were found even in many 
uncommon strains, gyrase mutations and associated ﬂ  uoro-
quinolone resistance alone cannot explain the high preva-
lence of ribotypes 001 and 027. 
Conclusions
We describe the dissemination and antimicrobial drug 
susceptibility of ribotypes causing severe CDI in Germany 
in 2008. We found that ribotype 001 was the most prevalent 
and widespread ribotype, found in 70% of submitting hos-
pitals. Although dissemination of ribotype 027 was more 
restricted, recent studies in England and Canada demon-
strated that ribotype 027 had the ability to replace type 001 
within a few years. In England, ribotype 001 had accounted 
for ≈55% of all CDI cases in the late 1990s but was reduced 
to 8% in 2008; during the same period, the proportion of 
DISPATCHES
676  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 4, April 2010
Figure 2. Approximate geographic dissemination of PCR ribotype 
001, 078, and 027 of Clostridium difﬁ  cile in hospitals in Germany 
in 2008. Green dots indicate hospitals with C. difﬁ  cile ribotype 001 
infections, blue squares hospitals with ribotype 078 infections, and 
red stars hospitals with ribotype 027 infections.
Table 1. Mean MICs of Clostridium difficile PCR ribotypes for 
metronidazole and vancomycin 
PCR ribotype (no.) 
Metronidazole,
mean MIC, mg/L 
Vancomycin, mean 
MIC, mg/L 
001 (303)  0.056  1.54
078 (46)  0.071  1.6
027 (51)  0.06 1.42
014 (21)  0.05 1.58
046 (14)  0.041  1.55
012 (14)  0.054  1.96
015 (6)  0.071  1.92C. difﬁ  cile, Germany
ribotype 027 had increased to 41% (8). Similarly, studies in 
Quebec showed a radical change from ribotype 001 strains 
accounting for 84% of isolates in 2000–2001 to 80% type 
027 isolates in 2003–2004 (14). This change was associ-
ated with increasing rates of CDI illness and death. It there-
fore seems advisable to increase infection control measures 
to curb the spread of ribotype 027 in Germany. 
Present data suggest that the dissemination of 027 
strains in Germany is restricted to the southwest (Figure 
2). Therefore, ribotype 027 cannot be the causative agent 
of increasing nationwide CDI incidence rates. Thus, in-
creased infection control efforts should not be restricted to 
the exposure of ribotype 027 because severe CDI courses 
are caused by all toxigenic C. difﬁ  cile strains.
To investigate if other traits (e.g., sporulation) or just 
random, stochastic events may determine the success of par-
ticular strains, a more detailed understanding of C. difﬁ  cile 
population structure is necessary. Therefore, international 
investigations based on portable genotyping procedures 
(15) including isolates from both, CDI and asymptomatic 
carriage, would considerably improve current knowledge.
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Table 2. Resistance to moxifloxacin and levofloxacin among the 5 PCR ribotypes of Clostridium difficile most common in Germany, 
2008 
PCR ribotype (no.) 
No. (%) isolates, resistant to 
moxifloxacin (MIC >4 mg/L) 
No. (%) isolates, resistant to 
levofloxacin (MIC >4 mg/L) 
Amino acid substitution 
GyrA GyrB 
001 (303)  301 (99)  301 (99)  Thr-82-Ile, Asp-71-Glu 
078 (46)  29 (63)  30 (65)  Thr-82-Ile, Thr-82-Ala  Asp-426-Asn 
027 (51)  51 (100)  51 (100)  Thr-82-Ile 
014 (21)  2 (9)  2 (9)  Thr-82-Ile  Glu-466-Lys 
046 (14)  14 (100)  14 (100)  Thr-82-Ile 